Plain-English translation of NCT06641713 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial compares two minimally invasive treatments for large liver cancer (tumors 10 cm or bigger). Both treatments work by delivering medicine directly to the tumor through blood vessels in the liver. One approach, called TACE, combines chemotherapy with blocking blood flow to starve the tumor. The other, called HAIC, uses hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin — chemotherapy drugs given directly into the liver's blood supply every 3 to 4 weeks. Researchers want to learn which method helps patients with large, advanced liver cancer live longer and feel better.
Large liver tumors are difficult to treat and carry a poor outlook. The standard TACE approach can struggle to reach all parts of a huge tumor, and blocking blood flow too aggressively can cause dangerous inflammation. This study exists to find out whether delivering chemotherapy directly into the liver artery (HAIC) might offer better control of the disease and safer outcomes for patients with large, advanced tumors.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be assigned to receive one of the two treatments. With TACE, doctors insert a thin catheter into the artery feeding your tumor and deliver chemotherapy while blocking blood flow — this may be done once or in multiple sessions. With HAIC, you receive chemotherapy infusions directly into the liver artery every 3 to 4 weeks. Throughout the study, you'll have regular visits for scans, blood tests, and check-ups to monitor how well the treatment is working and any side effects. The study involves about 664 participants across multiple hospitals.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Sponsor
Sun Yat-sen University
Collaborators
Chinese PLA General Hospital
Enrollment target
~664 participants
Started
October 2024
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qunfang Zhou, MD
Chinese PLA General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.